MedTrace Logo

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

NCT04391556 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2025-08-14

No results posted yet for this study

Summary

Evaluation of the interest of PET-PSMA imaging potentiated by androgen blockade in patients with biological relapse or persistent biological disease of a localized prostatic adenocarcinoma after initial treatment

Conditions

  • Prostate Adenocarcinoma

Interventions

DRUG

Firmagon

120 mg subcutaneous Injection of Firmagon after a TEP-PSMA

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Anne-Laure GIRAUDET, MD · Centre Leon Berard

  • David KRYZA, MD · Centre Leon Berard

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2023-05-02
Completion
2024-04-03

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391556 on ClinicalTrials.gov